Recent updates and emerging therapies in essential thrombocythemia

In this video, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, comments on promising emerging therapies for the management of essential thrombocythemia (ET), including pegylated interferon agents and immunotherapeutic approaches targeting mutant calreticulin (CALR). Prof. Odenike highlights that this is an exciting time in the field of ET, and she looks forward to further data and advancements in this disease area. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.